Synopsis
Identify malignant pleural mesothelioma, obtain adequate tissue without avoidable procedural harm, and integrate pleural symptom control, oncological treatment and occupational support.
- Malignant pleural mesothelioma is a tumour of mesothelial surfaces, strongly associated with previous asbestos exposure and often appearing decades after the relevant work or environmental contact.
- Ask beyond job titles: construction, shipyards, lagging, demolition, railway work, boiler maintenance, asbestos-contaminated clothing and renovation of older buildings can all reveal exposure.
- Progressive unilateral chest pain, dyspnoea, weight loss and a recurrent unilateral pleural effusion are common; chest-wall restriction may become prominent as the pleura encases the lung.
- Contrast-enhanced CT optimised for pleural assessment is the core anatomical investigation; nodular circumferential pleural thickening, mediastinal pleural involvement and fissural nodularity raise concern.
- Negative pleural-fluid cytology does not exclude mesothelioma. Histological confirmation with sufficient tissue and specialist immunohistochemistry is usually required.
- Plan the biopsy route with the pleural or thoracic team, because image-guided core biopsy and thoracoscopy have different yields, anaesthetic burdens and opportunities for fluid control.
- Do not use serum or pleural biomarkers as stand-alone diagnostic tests and do not request PET-CT reflexively after talc pleurodesis, which can cause persistent inflammatory uptake.
- Pleural-fluid control should reflect lung re-expansion, prognosis and patient preference: indwelling pleural catheter, talc pleurodesis or selected combined strategies require specialist assessment.
- Routine prophylactic radiotherapy to pleural procedure tracts is not recommended; new focal tract pain or a nodule should instead trigger clinical review.
- Systemic treatment eligibility is dynamic. Check the live NICE appraisal, pathology, performance status, comorbidity and jurisdictional commissioning decision at the mesothelioma MDT rather than copying a fixed regimen.
Key red flags
Unilateral pleural effusion with nodular thickening, circumferential rind, mediastinal pleural involvement, fissural nodularity, volume loss or chest-wall invasion is concerning. Pleural plaques support asbestos exposure but neither prove nor exclude mesothelioma.
Marked hypoxaemia, inability to speak comfortably, haemodynamic instability or mediastinal shift requires urgent assessment for a large effusion, pneumothorax, pulmonary embolism, infection or another acute complication rather than assuming routine tumour progression.
New severe vertebral, neuropathic or procedure-tract pain may reflect chest-wall, rib, neural or spinal involvement. Focal neurological signs require emergency imaging and cancer-team escalation.
Investigation priorities
Confirm fluid and choose a safe pleural access site.
Management branches
Unexplained unilateral effusion or pleural thickening with clinical concern for malignancy.
- Take a detailed occupational, household and environmental exposure history while arranging thoracic ultrasound and contrast-enhanced pleural CT through the local rapid pleural pathway.
- Sample fluid once if present for biochemical, microbiological and cytological assessment, but anticipate that mesothelioma often requires tissue and avoid serial low-yield aspirations.
- Review imaging with the pleural team and choose image-guided core biopsy or thoracoscopy to obtain enough tissue for invasion, subtype and the required ancillary tests.
- Have pathology reviewed by an experienced thoracic pathologist, complete stage and fitness assessment, and discuss the case at a specialist mesothelioma MDT before treatment is framed.